-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Entering the end of November, the 2021 annual performance forecasts of listed companies have also begun to surface
.
Data show that as of November 23, nearly 30 A-share companies have announced their 2021 annual performance forecasts, and more than half of them are profitable
.
From the perspective of the industry, the companies with pre-increasing net profits are mainly concentrated in the pharmaceutical, electronic, chemical and other industries, reaching 4, 3, and 3 respectively
.
The four pharmaceutical companies that have anticipated net profit growth in 2021 include Yan'an Bikang, Hualan, and Zuoli Pharmaceuticals.
Among them, Yan'an Bikang, Hualan, and Zuoli have all doubled their growth
.
Yan'an Bikang is a modern large-scale pharmaceutical enterprise group integrating raw materials, Chinese patent medicines, chemical drugs, biological preparations, vaccine research and development, health products, and health drink production and marketing
.
While the company disclosed its three-quarter report on October 29, 2021, it is expected that the net profit attributable to shareholders of the listed company in 2021 will be 950-1.
0 billion yuan, a year-on-year increase of 188.
72%-193.
39%, and the basic earnings per share will be 0.
6199-0.
6526 yuan
.
The performance changes were mainly contributed by the subsidiary Jiangsu Jiujiu Technology
.
The subsidiary's new energy products were affected by market demand, and the production capacity was released.
At the same time, the market price increased and other reasons led to the increase in profits, which had a positive impact on the company's performance growth; the new materials sector also increased profits due to the release of production capacity and other reasons
.
In addition, the company's subsidiaries received relevant subsidies, which had a greater impact on profits
.
Hualan shares are confident in the growth of the 2021 annual performance.
According to the current market environment and the company’s operating conditions, the company expects to achieve an operating income of approximately 705 million to 953 million in 2021, an increase of approximately 57.
89% over the same period in 2020.
113.
61%; in 2021, the net profit attributable to the owners of the parent company is expected to be approximately 197 million to 266 million yuan, an increase of approximately 141.
64% to 226.
92% over the same period in 2020
.
The company is mainly engaged in the R&D, production and sales of packaging materials for direct contact injection drugs.
The main products include various types of coated rubber stoppers, conventional rubber stoppers, etc.
.
Zuoli Pharmaceutical has also lived up to expectations.
It is estimated that the net profit attributable to shareholders of listed companies in 2021 will be between 170 million yuan and 187 million yuan, a year-on-year increase of 91.
44-110.
58%
.
This is an enterprise that produces modern biological Chinese medicine products based on the bio-fermentation technology of medicinal fungi.
At present, it is mainly engaged in the research and development, production and sales of medicinal fungi Wuling and Bailing series products, Lingze tablets, Chinese herbal medicine pieces and Chinese medicine formula granules
.
However, there are profits and losses.
For example, Berry Gene's net profit has a large pre-cut
.
This is an enterprise dedicated to the comprehensive transformation of gene sequencing technology to clinical applications, and refined products and services in the fields of reproductive health, genetic disease detection, tumor screening, and scientific and technological services
.
Berry Gene’s announcement on October 30, 2021 shows that the company’s 2021 net profit will lose 60 million yuan to 90 million yuan, and the profit for the same period last year is about 211 million yuan, which is expected to fall from profit to loss by about 128%-143% year-on-year.
.
As for the reasons for the pre-depletion of performance, the company said that the main reason is the decrease in the demand for pre-production testing services
.
During the reporting period, the company's main equipment NexSeqCN500 increased significantly, but due to the low level of sales gross profit, the company's overall performance level did not increase significantly
.
The company stated that it will give full play to the equipment's linkage with other products and services, turn the equipment into a full-platform testing equipment, increase the sales of the equipment in the microbiology field and third-party inspection agencies, and drive genetics, tumors, microorganisms, etc.
Sales of relevant reagents in the field
.
.
Data show that as of November 23, nearly 30 A-share companies have announced their 2021 annual performance forecasts, and more than half of them are profitable
.
From the perspective of the industry, the companies with pre-increasing net profits are mainly concentrated in the pharmaceutical, electronic, chemical and other industries, reaching 4, 3, and 3 respectively
.
The four pharmaceutical companies that have anticipated net profit growth in 2021 include Yan'an Bikang, Hualan, and Zuoli Pharmaceuticals.
Among them, Yan'an Bikang, Hualan, and Zuoli have all doubled their growth
.
Yan'an Bikang is a modern large-scale pharmaceutical enterprise group integrating raw materials, Chinese patent medicines, chemical drugs, biological preparations, vaccine research and development, health products, and health drink production and marketing
.
While the company disclosed its three-quarter report on October 29, 2021, it is expected that the net profit attributable to shareholders of the listed company in 2021 will be 950-1.
0 billion yuan, a year-on-year increase of 188.
72%-193.
39%, and the basic earnings per share will be 0.
6199-0.
6526 yuan
.
The performance changes were mainly contributed by the subsidiary Jiangsu Jiujiu Technology
.
The subsidiary's new energy products were affected by market demand, and the production capacity was released.
At the same time, the market price increased and other reasons led to the increase in profits, which had a positive impact on the company's performance growth; the new materials sector also increased profits due to the release of production capacity and other reasons
.
In addition, the company's subsidiaries received relevant subsidies, which had a greater impact on profits
.
Hualan shares are confident in the growth of the 2021 annual performance.
According to the current market environment and the company’s operating conditions, the company expects to achieve an operating income of approximately 705 million to 953 million in 2021, an increase of approximately 57.
89% over the same period in 2020.
113.
61%; in 2021, the net profit attributable to the owners of the parent company is expected to be approximately 197 million to 266 million yuan, an increase of approximately 141.
64% to 226.
92% over the same period in 2020
.
The company is mainly engaged in the R&D, production and sales of packaging materials for direct contact injection drugs.
The main products include various types of coated rubber stoppers, conventional rubber stoppers, etc.
.
Zuoli Pharmaceutical has also lived up to expectations.
It is estimated that the net profit attributable to shareholders of listed companies in 2021 will be between 170 million yuan and 187 million yuan, a year-on-year increase of 91.
44-110.
58%
.
This is an enterprise that produces modern biological Chinese medicine products based on the bio-fermentation technology of medicinal fungi.
At present, it is mainly engaged in the research and development, production and sales of medicinal fungi Wuling and Bailing series products, Lingze tablets, Chinese herbal medicine pieces and Chinese medicine formula granules
.
However, there are profits and losses.
For example, Berry Gene's net profit has a large pre-cut
.
This is an enterprise dedicated to the comprehensive transformation of gene sequencing technology to clinical applications, and refined products and services in the fields of reproductive health, genetic disease detection, tumor screening, and scientific and technological services
.
Berry Gene’s announcement on October 30, 2021 shows that the company’s 2021 net profit will lose 60 million yuan to 90 million yuan, and the profit for the same period last year is about 211 million yuan, which is expected to fall from profit to loss by about 128%-143% year-on-year.
.
As for the reasons for the pre-depletion of performance, the company said that the main reason is the decrease in the demand for pre-production testing services
.
During the reporting period, the company's main equipment NexSeqCN500 increased significantly, but due to the low level of sales gross profit, the company's overall performance level did not increase significantly
.
The company stated that it will give full play to the equipment's linkage with other products and services, turn the equipment into a full-platform testing equipment, increase the sales of the equipment in the microbiology field and third-party inspection agencies, and drive genetics, tumors, microorganisms, etc.
Sales of relevant reagents in the field
.
